Announcement PDF RNS Number : 2111I Shield Therapeutics PLC 11 August 2021 Shield Therapeutics plc ("Shield or the "Company" or the "Group") Notice of Results London, UK, 11 August 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), will announce its interim results for the six months ended 30 June 2021 on Tuesday 17 August 2021. Analyst briefing A briefing open to analysts will take place remotely via video conference call on Tuesday 17 August 2021 at 14.00 (BST). If you would like the details of this call please contact Walbrook PR on shield@walbrookpr.com. For further information, please contact: Shield Therapeutics plc Greg Madison (CEO) Hans-Peter Rudolf (CFO) Peel Hunt LLP - Nominated Adviser & Joint Broker +44 (0) 191 511 8500 +44 (0) 20 7148 8900 James Steel / Christopher Golden finnCap Ltd - Joint Broker Geoff Nash / Alice Lane/ George Dollemore +44 (0) 20 7220 0500 Walbrook PR - Financial PR & IR Adviser Paul McManus / Lianne Cawthorne/ Alice Woodings +44 (0) 20 7933 8780 or shield@walbrookpr.com About Shield Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK, Switzerland and Australia and has exclusive IP rights until the mid-2030s. The Group is currently launching Accrufer® in the US. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END NORBLGDIDGBDGBG